ABVC - Company ID 0001173313
The table below shows ABVC BIOPHARMA, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $296.00K | $509.59K | $152.43K | $969.78K | $355.80K | $483.05K |
| Cost of revenue | - | $763.00 | $302.04K | $286.42K | $5.09K | $18.72K |
| Gross profit | - | $508.83K | -$149.61K | $683.37K | $350.71K | $464.33K |
| R&D | $121.08K | $179.27K | $1.06M | $2.69M | $1.00M | $549.66K |
ABVC BIOPHARMA, INC. reported annual revenue of $296.00K for fiscal year 2025. That is down 41.9% from $509.59K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.89M |
| $2.26M |
| $5.37M |
| $6.07M |
| $5.75M |
| $4.27M |
| Operating income | -$7.15M | -$4.71M | -$6.77M | -$15.11M | -$11.71M | -$8.51M |
| Income tax | $24.15K | -$110.54K | $256.01K | $797.78K | $825.02K | -$220.35K |
| Net income | -$7.91M | -$4.90M | -$7.79M | -$16.42M | -$12.84M | -$10.59M |
| EPS (diluted) | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$0.51 | -$0.50 |